ABBV-552 Dose A for Alzheimer's Disease

Health Synergy Clinical Research LLC /ID# 247726, Okeechobee, FL
Alzheimer's DiseaseABBV-552 - Drug
50 - 90
All Sexes
What conditions do you have?

Study Summary

This trial is testing an experimental drug to treat Alzheimer's disease. 240 people aged 50-90 with mild Alzheimer's will take it orally once daily and be monitored.

Eligible Conditions
  • Alzheimer's Disease

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: From Baseline (Week 0) through Week 12

Week 12
Change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) score

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Trial Design

4 Treatment Groups

ABBV-552 Dose A
1 of 4
ABBV-552 Dose B
1 of 4
ABBV-552 Dose C
1 of 4
Placebo for ABBV-552
1 of 4

Experimental Treatment

Non-Treatment Group

240 Total Participants · 4 Treatment Groups

Primary Treatment: ABBV-552 Dose A · Has Placebo Group · Phase 2

ABBV-552 Dose A
Experimental Group · 1 Intervention: ABBV-552 · Intervention Types: Drug
ABBV-552 Dose B
Experimental Group · 1 Intervention: ABBV-552 · Intervention Types: Drug
ABBV-552 Dose C
Experimental Group · 1 Intervention: ABBV-552 · Intervention Types: Drug
Placebo for ABBV-552
PlaceboComparator Group · 1 Intervention: Placebo for ABBV-552 · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from baseline (week 0) through week 12

Who is running the clinical trial?

AbbVieLead Sponsor
871 Previous Clinical Trials
479,007 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
324 Previous Clinical Trials
124,244 Total Patients Enrolled

Eligibility Criteria

Age 50 - 90 · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

What potential risks are associated with administering ABBV-552 Dose A to patients?

"As ABBV-552 Dose A is currently in Phase 2 of trials, our team at Power has assigned it a safety rating of 2. Meaning, while there are some data points supporting its security profile, none have been found that support efficacy." - Anonymous Online Contributor

Unverified Answer

Who is eligible to volunteer for this research endeavor?

"This clinical trial is enlisting individuals diagnosed with Alzheimer's Disease that are aged between 50 and 90. It hopes to recruit up to 240 volunteers for the study." - Anonymous Online Contributor

Unverified Answer

Is eligibility for this research study being extended to individuals of advanced age?

"This clinical trial has established a minimum age limit of 50 and an upper boundary of 90 for potential participants." - Anonymous Online Contributor

Unverified Answer

Is this research currently recruiting participants?

" confirms that this study, which was initially published on April 2nd 2023 and most recently edited on March 6th 2023, is not presently searching for participants. However, there are 540 other clinical trials in need of patients at the moment." - Anonymous Online Contributor

Unverified Answer

How many venues are presently hosting this experimental research?

"For this clinical trial, 60 sites are operating such as Alliance for Research in Long Beach (ID# 246492), Pharmacology Research Institute (PRI) located in Los Alamitos (Wake) (ID# 248891), and Artemis Institute for Clinical Research based out of Riverside (ID# 250677). Other locations are also included." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.